9-3-10 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com

Stephen Bernard, AP Business Writer

Stocks extend September rally after jobs report

Stocks extend September rally after jobs data eases fears about economic slowdown

NEW YORK (AP) — Stocks extended their rally Friday after an encouraging report on jobs lifted hopes about the pace of economic growth.

The Dow Jones industrial average about 52 points in late morning trading. Broader indexes also rose. Stocks moved off their morning highs after a report indicated the services sector grew at a slower pace than expected last month.

The jobs reported “created a bit of optimism, but there’s still a degree of caution,” said Nick Kalivas, vice president of financial research for MF Global. The services sector report renewed some skepticism, Kalivas said.

The Labor Department said private employers added 67,000 jobs in August, more than the 41,000 economists polled by Thomson Reuters had forecast. While the report added a small dose of optimism, it also shows that the economic recovery is still tenuous.

Read More >>

Yesterday’s Top Performing Small Cap Stock:

Curaxis Pharmaceutical Corp. CURX

Curaxis Pharmaceutical Corp. was a SmallCapVoice.com top performer closing up over 10% on trading volume of 21,106 shares.

Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer’s disease and multiple cancers. Curaxis’ therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism foCHfeedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer’s disease and various cancers. We believe our discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer’s patients and in multiple tumors will enable us to develop significant new treatments for Alzheimer’s disease as well as many cancers.

Today’s SmallCapVoice.com Hot Stock to Watch:

Kore Nutrition, Inc. KORE

Kore, through its wholly-owned subsidiary, ALL IN, is engaged in the business of developing, producing, and selling non-alcoholic beverages. It produces premium energy drinks and an enhanced purified water under the brand name, ALL IN(TM) Energy, to suit the demands of an active world. Unlike competitive energy drinks, which can lack great taste and occasionally create a mere energy blip, ALL IN(TM) Energy is a premium sugar free product, with no carbohydrates, and less than 10 calories per can. ALL IN(TM) Energy uses herbs, vitamins and amino-acids to provide a balanced and sustained sharpening of focus and pure energy. ALL IN(TM) Energy drinks are available in three unique and delicious flavors: Citrus, Grape and Acai Berry. ALL IN also offers a premium water that uses advanced technologies, and preliminary research suggests that ALL IN(TM) water is a faster hydrator than ordinary tap water and other mineral waters. Legendary poker champion Johnny Chan has joined together with fellow top poker professionals, who all endorse ALL IN(TM) Energy drinks. Kore intends to expand the production, sales and distribution of ALL IN(TM) Energy drinks and water over the next twelve months.


Other Small Cap News

PostRock Energy Corporation PSTR

PostRock Announces $60 Million Investment by White Deer Energy

OKLAHOMA CITY, Sept. 2, 2010 (GLOBE NEWSWIRE) — PostRock Energy Corporation PSTR (“PostRock or the “Company”) today announced that White Deer Energy L.P. (“White Deer”) has agreed to invest $60 million of equity in the Company. White Deer is a recently formed energy private equity firm. In connection with the investment, PostRock’s debt will be reduced and its credit agreements restructured.

Read More >>


BioDelivery Sciences International, Inc. BDSI

BioDelivery Sciences Announces Positive Meeting with FDA on a Streamlined ONSOLIS REMS with Broadened Distribution

Recently Submitted REMS Amendment Seeks to Better Facilitate Physician Prescribing for Appropriate Patients and Improve Patient Access

RALEIGH, N.C.–(BUSINESS WIRE)–BioDelivery Sciences International, Inc. BDSI today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).

Read More >>


Celsion Corporation CLSN

Celsion Receives SBIR Grant To Expand Its Technology Platform

Activities to focus on additional applications for the Company’s unique heat-activated liposomal technology encapsulating carboplatin

COLUMBIA, Md., Sept. 2 /PRNewswire-FirstCall/ –Celsion Corporation CLSN, a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, “New Thermal Sensitive Carboplatin Liposomes for Cancer”. This funding will support the Company’s efforts to develop its proprietary heat-activated liposomal technology in combination with carboplatin, an approved and frequently used oncology drug for treatment of a wide range of cancers. The grant is valued at approximately $200,000 and will support formulation development and preclinical efficacy studies in collaboration with Duke University.

Read More >>


Cerus Corporation CERS

Cerus and the Swiss Red Cross Report Successful Outcome of INTERCEPT Blood System Platelet Study

CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation CERS announced today the successful outcome of a multi-year trial of INTERCEPT-treated platelet components conducted at the Swiss Red Cross Blood Center in Basel, Switzerland. The INTERCEPT Blood System is a pathogen inactivation treatment designed to protect against transfusion-transmitted diseases.

Read More >>


Derma Sciences, Inc. DSCI

Derma Sciences Novel XTRASORB® HCS Dressings Receive Federal Reimbursement Codes; Join Foam and Classic Dressings for Complete Coverage of Product Category

PRINCETON, N.J.–(BUSINESS WIRE)–Derma Sciences, Inc. DSCI, a medical device and pharmaceutical company focused on advanced wound care, announces that all five products in its novel line of XTRASORB® HCS Dressings have received Healthcare Common Procedural Coding System (HCPCS) codes. These codes – A6234 through A6238 – were awarded by the Centers for Medicare and Medicaid Services (CMS), and allow healthcare providers to bill for the dressings beginning immediately.

Read More >>

About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide. Known for its ability to help emerging growth companies build a following among retail and institutional investors, SmallCapVoice.com utilizes its stock newsletter to feature its audio interviews, as well small cap company’s financial news releases. SmallCapVoice.com also offers individual investors with all the tools they need to make informed decisions about the stocks they are interested in. Tools like our stock charts, stock alerts, and our company information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets.

The SmallCapVoice.com, Inc. Daily Highlights is an electronic publication, and is for informational purposes only. The Small Cap Voice Daily Highlights covers both client and non client issuers. Non client issuer’s news is listed under other small cap news. SmallCapVoice is an electronic publication providing information on selected public companies. All companies profiled on this website pay cash or restricted stock to SmallCapVoice as consideration for the electronic dissemination of the company’s information and our comments about the company. Section 17(b) of the Securities Act of 1933 requires that SmallCapVoice fully disclose the type consideration (i.e. cash, restricted stock, and restricted stock with registration rights, stock options, stock warrants, or other type consideration) and the specific amount of the consideration our company receives or will receive, directly or indirectly, from an issuer, underwriter, or dealer. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell the securities of the profiled companies. SmallCapVoice is not a registered investment advisor or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. The information contained in our website, e-mail communications and publications are carefully compiled by SmallCapVoice from public sources that we believe to be reliable. SmallCapVoice, however, does not guarantee the accuracy of any information contained in our website, e-mail communications or publications. This material is not a substitute for either one’s own thorough investigation of an investment opportunity or the exercise of good business judgment. SmallCapVoice does not endorse, independently verify, or assert the truthfulness or reliability of any statements or data obtained from third party sources that are published by us about the profiled companies in our website articles, e-mail communications or publications, but we do not publish information that we know is incorrect. Investors should not rely solely on the information contained in our website, e-mail communications or publications when making investment decisions. Instead, investors should use the information provided on the profiled companies as a starting point for conducting additional research that will permit them to form their own opinions regarding the appropriateness of an investment in the profiled company’s securities. SmallCapVoice does not warrant, represent or guaranty that there has been no change in the affairs of the profiled company since the date that information was published on this website, in e-mail communications or in our publications regarding a profiled company or after the date of the profiled company’s press releases or other information disseminated via our website or publications.  If you become aware of any change of circumstances related to any website article, e-mail communication or publication, please notify us immediately.  See the Contact Us page for the appropriate e-mail address. The information contained in our website, e-mail communications and publications pertains to microcap, small cap and/or other thinly traded securities which by their very nature involve an extremely high degree of risk. An investment in these type of securities could result in the loss of some or all of an investment in the company. In addition, due to the illiquid nature of some of these securities, an investor may find encounter difficulties in liquidating the securities. SmallCapVoice may liquidate the stock consideration it receives at any time it deems it appropriate to do so after the required six-month holding period has run after the completion of the services for which SmallCapVoice was paid in stock. The liquidation of our stock may have a negative impact on the securities of the company liquidated, including decreased market value and/or dilution of the company’s securities. The following companies have paid, and/or have agreed to pay SmallCapVoice to: distribute the company’s information and reports on this website, to send e-mail communications; to send publications by mail, to post company Internet links on our website, and to compile and/or to distribute reports in an e-mail newsletter.

We encourage our readers to use caution when investing and educate themselves at the web sites of the Securities and Exchange Commission (“SEC”) at www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at www.nasd.com. We encourage you to study the SEC’s policies regarding online newsletters at http://www.sec.gov/answers/newsltr.htm. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC’s EDGAR page. The NASD has published information on how to invest carefully at its web site. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our site.

Contact:

Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com

Twitter StumbleUpon Facebook LinkedIn Technorati Favorites Yahoo Buzz Delicious Digg Fark Google Buzz NewsVine Netvibes Share PrintFriendly Google Gmail MySpace Blogger Post AOL Mail Yahoo Bookmarks Windows Live Spaces WordPress Yahoo Mail Share/Bookmark

Related posts

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Industrial MachineryIndustrialsUtilities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!